BioTuesdays

Category - Markets

Protagonist Therapeutics

Leerink starts Protagonist Therapeutics at outperform

Leerink Partners launched coverage of Protagonist Therapeutics (NASDAQ:PTGX) with an “outperform” rating and $17 price target in 12 months. The stock closed at $12.08 on Friday. Protagonist is aiming to become the...

Endologix

Leerink starts Endologix at market perform

Leerink Partners initiated coverage of Endologix (NASDAQ:ELGX) with a “market perform” rating and $13 price target. The stock closed at $12.22 on Friday. Endologix is the largest abdominal aortic aneurysm (AAA) pure...

Atossa Genetics

Atossa Genetics prices common stock offering

Atossa Genetics (NASDAQ:ATOS) has priced a public offering of 1,150,000 common shares at a price of $2.50 a share for gross proceeds of about $2,875,000. Atossa Genetics also granted underwriters a 45-day option to...

OPKO Health

OPKO completes acquisition of Transition Therapeutics

OPKO Health (NASDAQ:OPK) has completed the acquisition of Transition Therapeutics (NASDAQ:TTHI; TSX:TTH) by way of a plan of arrangement. Under the transaction, shareholders of Transition will receive about 6.4 million...

Neuralstem

Roth starts Neuralstem at buy

Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday. Analyst Joseph Pantginis writes that Neuralstem has undergone a...

Actinium

Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the...

Tactile Systems Technology

Analysts start Tactile Systems at buy, outperform

Analysts at BTIG Research, Piper Jaffray and William Blair initiated coverage of Tactile Systems Technology (NASDAQ:TCMD) with “buy,” “overweight” and “outperform” ratings, respectively. Tactile makes pneumatic...

Leerink

Leerink upgrades Cardiovascular Systems

Leerink Partners upgraded Cardiovascular Systems (NASDAQ:CSII) to “outperform” and raised its price target to $30 from $23. The stock closed at $22.60 on Friday. “Now with two solid quarters in a row of stable-to...

William Blair

WB starts 4 chronic Hep B biotechs at outperform

William Blair initiated coverage at “outperform” of four biotech companies that are strategically positioned to benefit from the hepatitis B virus frontier. “Curing chronic hepatitis B infections is the next frontier...

Leerink

Leerink downgrades Mirna to market perform

Leerink Partners downgraded Mirna Therapeutics (NASDAQ:MIRN) to “market perform” from “outperform” and lowered its price target to $4 from $10, citing added uncertainties around the development path and safety profile...